Graypoint LLC’s ResMed RMD Stock Holding History

Graypoint LLC’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$283K	Buy	1,097 +125	+13%	+$29.8K	0.02%	448
2025 Q1	$218K	Sell	972 -5	-0.5%	-$1.17K	0.01%	479
2024 Q4	$224K	Buy	977 +21	+2%	+$5.06K	0.01%	479
2024 Q3	$233K	Buy	+956	New	+$214K	0.02%	457

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Graypoint LLC's RMD Position: Q2 2025 in Review

Graypoint LLC increased its ResMed (RMD) stake by 13% in Q2 2025, buying an estimated $29.8K and bringing the position to 1,097 shares worth $283K. The position accounts for 0.02% of the portfolio, ranked #448.

Graypoint LLC first reported a position in RMD in Q3 2024 and has held it in 4 quarters since. 919 funds tracked by Wall St. Rank hold RMD as of Q2 2025.

Graypoint LLC held 1,097 shares of ResMed worth $283K as of Q2 2025.
Graypoint LLC bought 125 ResMed shares in Q2 2025, an estimated $29.8K.
ResMed made up 0.02% of Graypoint LLC's portfolio in Q2 2025, its #448 holding.
Graypoint LLC first reported a position in ResMed in Q3 2024 and has held it in 4 quarters since.
919 funds tracked by Wall St. Rank held ResMed as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.